Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Amylyx Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZA™ in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the second quarter of 2023 and cash, cash equivalents and short-term investments of $357.3 million at June 30, 2023 ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
07/26/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline with first participant dosed in Phase 2 HELIOS study of AMX0035 in Wolfram syndrome and planned initiation of a pivotal Phase 3 study in progressive supranuclear palsy anticipated this year ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
03/21/2023 8-K Appointed a new director
Docs: "Non-Employee Director Compensation Policy"
03/13/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results • Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progress • Regulatory review ongoing in the EU • Karen Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Company's Board of Directors • Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
02/14/2023 8-K Regulation FD Disclosure  Interactive Data
12/06/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results ˗ RELYVRIO™ approved for the treatment of ALS in adults and now commercially available in the U.S., representing second product launch for Amylyx worldwide ˗ Commercial launch of ALBRIOZA™ in Canada continues to progress ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
11/02/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results"
08/11/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
01/11/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Fourth Amended and Restated Certificate of Incorporation of Amylyx Pharmaceuticals, Inc",
"Second Amended and Restated Bylaws of Amylyx Pharmaceuticals, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy